Conference Programme

We encourage you to check back regularly to view the most up-to-date version of the program.

 

THURSDAY 28^th May 2026

1530                   Registration

1600                   Local session - Dag Fosmark & Goran Petrovski

1645                   Roche sponsored mini-symposium - Evolving Treatment Strategies in Diabetic Macular Edema: Clinical Experience with Faricimab

1730                   Bus to welcome reception at City Hall

1830-2000       EAsDEC Opening Ceremony followed welcome reception at City Hall

 

FRIDAY 29^th MAY 2026

Registration

0900                   Welcome - Dag Fosmark

0915                   SESSION 1: CLINICAL

Moderators: Stela Vujosevic and Christina Rennie

Rennie, UK. Optimising Anti-VEGF and corticosteroid use in centre-involved diabetic macular oedema: A validated UK Delphi consensus supporting individualised patient care. 5 mins + 2 mins questions

RAPID FIRE (4 mins/presentation)

Vujosevic, Italy. A randomized, active-controlled clinical trial of fluocinolone acetonide 0.19-mg intravitreal implant for diabetic macular oedema: visual acuity outcomes based on lens status – Results from the NEW DAY study

Charles O'Donovan, UK. Switching from Aflibercept to Faricimab in diabetic macular oedema: Real-world outcomes

Huber, Austria. One-year real-world outcomes after switching from Aflibercept to Faricimab in diabetic macular oedema

Ahmed, UK. Intravitreal Faricimab for treatment of diabetic macular oedema: Impressive real-world outcomes sustained at 52 weeks

Salvatore, UK.  Real-world dexamethasone implant (DEX-I) injection burden in diabetic macular oedema: insights from 10 UK sites using the mediSIGHT EMR

Peto, UK. Two-year effectiveness, durability and safety of Faricimab in eyes with diabetic macular oedema: Results from the UK FARWIDE-DME Study

Questions and discussion 12 mins

Moderators' conclusions 2 mins

 

1000                   DEBATE

‘A paradigm shift is needed in trial design for intravitreal agents in DME'

For – Reinier Schlingemann. Against – Philip Burgess

 

1030                   Coffee

 

1115                   SESSION 2: Imaging and Artificial Intelligence

Moderators: Goran Petrovski and Maria Cicinelli

Short talk: Goran Petrovski ‘Implementation of Artificial Intelligence in DR screening in Norway' (10 mins)

Free papers: 5 mins + 2 minutes Questions

McNally UK.  Creation of a validated OCT fluid segmentation gold standard to support AI development in DMO

Cicinelli, Italy. Intraretinal fluid redistribution as a dynamic biomarker of treatment response in diabetic macular oedema

Jeppesen, Denmark. Visual acuity is reduced with increasing central retinal thickness, higher age and female sex in diabetic macular oedema

Widmann-Sedlnitzky, Austria. Hard exudate and hyperreflective foci dynamics across anatomical response patterns in faricimab-treated diabetic macular oedema

Pignataro, Italy. Microaneurysm reflectivity as a prognostic biomarker for intravitreal treatment response in diabetic retinopathy

Almeida, Portugal. Retinal microvascular and neuronal findings in type 2 diabetes: Results from a screening programme

Marques, Portugal. Two-year longitudinal progression of microvascular changes in moderate to severe non-proliferative diabetic retinopathy: The RICHARD Study

Dag Fosmark – Anne Katrin Sjolie Memorial talk 5 minutes

The winner of the Anne Katrin Sjolie Student Prize:  

Kunze, Austria. Diabetic vascular and inflammatory microstructures followed over time by high-resolution adaptive optics imaging

Moderators' conclusions 4 minutes

 

1230                   Lunch (Poster presenters' priority)

 

1230-1500       POSTER SESSION

Poster Section 1. Clinical A

Moderators: Maria Grazia Pignataro and XXX

Gruszka-Goh, UK. Injection treatment intervals in eyes with DMO switching to 8mg Aflibercept

Wales, UK. Can telephone consultations enhance the diabetic ophthalmology service?

Leitão, Portugal. Early-onset high-risk proliferative diabetic retinopathy in type 1 diabetes: a rare case and 20-year cohort analysis

Chatziralli, Greece.  Randomized, controlled study to investigate the efficacy and safety of resveratrol vitamin supplements in patients with non-proliferative diabetic retinopathy without diabetic macular oedema (REVOLUTION study)

Tarasi, Romania. Early worsening of diabetic retinopathy after rapid glycaemic control: A case report highlighting vitamin D as a nutritional intervention

Masalkhi, Republic of Ireland, Diabetic Retinopathy Screening Outcomes in Pregnancy: A Review of the Pregnancy Pathway in the Irish National Diabetic Retinal Screening Programme.

 

Poster Section 2. Clinical B

Moderators: Andreas Pollreisz and XXX

Ferreira, Portugal. Fluocinolone acetonide after glaucoma surgery in diabetic macular oedema: clinical risk or safe therapeutic option?

Saraan, UK. Effectiveness and safety of intravitreal steroid therapy for diabetic macular oedema: A clinical audit at the Royal Liverpool University Hospital.

Peto, UK. Injection frequency, loading dose completion, and 12-month outcomes of anti-VEGF treatment in diabetic macular oedema

Madeira, Portugal. Sustained disease control with fluocinolone acetonide implant in refractory diabetic macular oedema: Real-world evidence

Earley, UK. Diabetic and surgical factors associated with progression of pseudophakic diabetic retinopathy, a 5 year follow up study

Bettencourt, Portugal. Acute bilateral cystoid macular oedema following SARS-CoV-2 vaccination in a type 1 diabetic patient: A case report

Tomić, Croatia. Citicoline shows potential in reducing the hard exudates in diabetic retinopathy

Similie, Denmark. Rapid glycaemic reduction and early worsening of diabetic retinopathy in type 1 diabetes: A Danish nationwide cohort study

Poster Section 3. Imaging and Artificial Intelligence

Moderators: Inês Pereira Marques and Signe Jeppesen

Carotenuto, Italy. OCT and OCTA phenotypes as predictors of durable response to aflibercept 8 mg in diabetic macular oedema: An 18-month real-world analysis

Chiosi, Italy. Artificial intelligence–guided inflammatory biomarkers to support a proactive dexamethasone implant regimen in diabetic macular oedema: A real-world study analysis

Pinto, Portugal. Microaneurysm counting as a biomarker for the hyperperfusion stage of nonproliferative diabetic retinopathy

Poster section 4. Screening
Moderators: Gier Bertelsen and Phil Burgess

Davies, UK. Feasibility of an alternative pathway for hospital referrals from Diabetic Eye Screening Wales (DESW) for people suspected with sight-threatening diabetic eye disease (diabetic maculopathy)

Babić, Croatia. Design and implementation of a national programme for diabetic retinopathy screening in Croatia: A telemedicine-based population health initiative

Sharif, Sweden. Quantifying diabetic retinopathy in the elderly: Long term screening outcomes

Jamison, UK. Rates of retinopathy and maculopathy at diabetes clinics in three regions of Tanzania

Meredith, UK. A review of people within the English National Diabetic Eye Screening Programme who were screened without mydriasis

Sauesund, Norway. Implementation of diabetic retinopathy screening in the Oslo Region, Norway: A Three-year pilot study

Rahim, UK. Post-COVID-19 barriers to diabetic retinopathy screening attendance: An updated systematic review

Piatti, Italy. Implementation of a reading centre for diabetic retinopathy screening in Piedmont region, Italy

Sproule, UK. The Diabetes Complications in Senior Adults (DCSA) Study: Diabetic eye disease in people over the age of 80 with diabetes in Northern Ireland

Ao, China. Establishing a regional diabetic eye screening system in Hinggan League, China

 

1430                   Coffee

 

15.00                  SESSION 3: Laboratory Experimental A

Moderators: Patrice Fort and Imre Lengyel

(5 min +2 min discussion)

Fort, USA.  The Mary Tyler Moore Vision Initiative Biorepository and Resource Center: Deep structural analysis of the neurovascular unit components as a function of diabetic retinal disease

Lengyel, UK. A Type 1 Diabetic Abcc6 /- mouse model reveals mechanisms of ectopic calcification and therapeutic potential of oral pyrophosphate

Su, Germany.  VE-cadherin Y685 phosphorylation is critical for neurovascular unit regulation during retinal angiogenesis

Ambrosio, Portugal.  Negative impact of a primary immune challenge triggered by lipopolysaccharide on the retina of diabetic rats

Lin, Germany.  MDM2 regulates integrin β8 expression in mouse diabetic retina

Arroba, Spain. Proteomic and inflammatory signatures associated with diabetic retinopathy in type 1 diabetes mellitus

Moderators' conclusions 3 mins

1545                   KEYNOTE: Professor emeritus. Trond G Jenssen, Nephrologist, Rikshospitalet, Oslo University Hospital

                              ‘An Eye for the Kidney' (20 mins + 10 mins Q/A)

1615                   Eva Kohner Lecture: Toke Bek. Introduced by RS

1645                   AGM + Lithuania introduction

1715                   Close

1730-2200       Dinner

 

SATURDAY 30^th May 2026

0900                   SESSION 4: SCREENING

Moderators: Maja Gran Erke, Gier Bertelsen and Laura Cushley

SHORT TALK: Maja Gran Erke, Norway. Update on diabetic eye screening in Norway (7 mins)

Jordan, UK. NHS Diabetic Eye Screening (DES) Research and Innovation Needs Assessment (RINA) (7 min)

Discussion 5 mins

Borjan, Croatia. Proliferative Diabetic Retinopathy in Young-Onset Type 1 Diabetes in Croatia: Risk Factors and a Predictive Economic Model for National Screening (5 min)

Haidar, UK. Progression of diabetic retinopathy from referral to treatment or vision loss: External validation, update and net clinical benefit of a multivariable prediction model (5 min)

Cushley, UK.  Diabetes Complications in Senior Adults (DCSA) Study: investigating diabetic eye disease, knowledge and opinions in people over 80 in Northern Ireland (NI) (5 min)

Vrabec, Croatia. First twelve-month results of diabetic retinopathy screening in Croatia: what we have done and achieved (5 min)

Discussion and moderators' conclusions 6 minutes

 

0945                   SESSION 5: TRANSLATIONAL

Moderators: Ingeborg Klassen and E Beli

(6 min + 2 min questions)

Jansson, Norway.  Light-adapted full-field electroretinography predicts diabetic retinopathy progression: A 10-year prospective cohort study

Peterson, Denmark.  The amplitude of spontaneous diameter oscillations in retinal arterioles is increased in patients with vision threatening diabetic retinopathy

Beli, UK.  The role of microglia circadian clock in diabetic retinopathy

Klaassen, The Netherlands. Retinal and cerebral microvascular changes in diabetes and Alzheimer's disease

Besic, Denmark. Clinical interpretation of inner retinal phenotypes in children and young adults with type 1 diabetes

Discussion and moderators' conclusions 5 minutes

1030                   Coffee

1100                   KEYNOTE: Per M Thorsby, Professor in medical biochemistry, Medical chair of department Hormone Laboratory, Specialised in endocrinology and internal medicine, Oslo University Hospital

Early detection of diabetes – finding the patient before the disease

 

1125                   KEYNOTE: Lars Krogvold, MD PhD, Head of diabetes unit, Pediatric department, Oslo University Hospital

 

Prevention and screening of type 1 diabetes

 

1150                   SESSION 6: RESEARCH HORIZONS

Moderators: Karl-Johan Hellgren and XXX

(6 mins plus 2 min for questions)

Torm, Denmark. Retinal neurophysiological and microvascular parameters in young patients with type 1 diabetes

Hellgren, Sweden. Methods to detect change in visual fields in diabetic patients followed over a ten-years period

Toma, Italy. Evaluation of quality of life with a novel computerised system and visual function in patients with centre-involving diabetic macular oedema

Al-Zubaidy, UK. Predicting anti-VEGF outcomes in centre-involving diabetic macular oedema using regression and multimodal deep learning: A real-world NHS cohort

Urbančič, Slovenia.  Association between macular pigment optical density, diabetes, and diabetic retinopathy

Yu, China. A gold nano-array SERS platform integrated with aptamer-antibody recognition enables non-invasive diagnosis and specific screening of diabetic retinopathy via tear biomarkers

Discussion and moderators' conclusions  7 minutes

1245                   Closing remarks and poster prize RS

1300                   Lunch

 

**Program timings are subject to change as it evolves.